bioRxiv · 10.1101/2020.06.12.148387
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
Abstract
The COVID-19 pandemic has had unprecedented health and economic impact, but currently there are no approved therapies. We have isolated an antibody, EY6A, from a late-stage COVID-19 patient and show it neutralises SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds tightly (KD of 2 nM) the receptor binding domain (RBD) of the viral Spike glycoprotein and a 2.6[A] crystal structure of an RBD/EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues of this epitope are key to stabilising the pre-fusion Spike. Cryo-EM analyses of the pre-fusion Spike incubated with EY6A Fab reveal a complex of the intact trimer with three Fabs bound and two further multimeric forms comprising destabilized Spike attached to Fab. EY6A binds what is probably a major neutralising epitope, making it a candidate therapeutic for COVID-19.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Zhou, D., Duyvesteyn, H. M. E., Chen, C.-P., Huang, C.-G., Chen, T.-H., Shih, S.-R., Lin, Y.-C., Cheng, C.-Y., Cheng, S.-H., Huang, Y.-C., Lin, T.-Y., Ma, C., Huo, J., Carrique, L., Malinauskas, T., Ruza, R. R., Shah, P., Tan, T. K., Rijal, P., Donat, R. F., Godwin, K., Buttigieg, K., Tree, J., Radecke, J., Paterson, N. G., Supasa, P., Mongkolsapaya, J., Screaton, G. R., Carroll, M. W., Jaramillo, J. G., Knight, M., James, W. S., Owens, R. J., Naismith, J. H., Townsend, A., Fry, E. E., Zhao, Y., Ren, J., Stuart, D. I., Huang, K.-Y. A.. 2020-06-13. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. https://doi.org/10.1101/2020.06.12.148387
Cite the original work for its findings. Save a collection to share your selection of sources.